Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 10/20 | 0.51 |
| ▸ | AGXT | P21549 | 5/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1520941 | 0.88 | IDO1 (0.53) | IDO1AGXTCYP3A4FFAR1FFAR4 | |
| SCHEMBL1520724 | 0.84 | IDO1 (0.56) | IDO1AGXTCYP3A4FFAR1FFAR4 | |
| SCHEMBL791733 | 0.83 | HTR7 (0.41) | DHFRTAAR1FFAR1FFAR4TDO2 | |
| SCHEMBL1520857 | 0.82 | IDO1 (0.54) | IDO1AGXTCYP3A4DHFR | |
| SCHEMBL12767532 | 0.80 | CYP2A6 (0.47) | IDO1CYP3A4FFAR1FFAR4 | |
| SCHEMBL1520778 | 0.78 | IDO1 (0.49) | IDO1AGXTCYP3A4FFAR1FFAR4 | |
| SCHEMBL14686334 | 0.77 | NUDT1 (0.44) | IDO1CYP3A4DHFRTAAR1FFAR1 | |
| SCHEMBL1520675 | 0.77 | IDO1 (0.56) | IDO1AGXTCYP3A4DPP4 | |
| SCHEMBL1520777 | 0.76 | IDO1 (0.47) | IDO1AGXTFFAR1FFAR4MAOB | |
| SCHEMBL1521194 | 0.76 | IDO1 (0.47) | IDO1AGXTCYP3A4FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227233-B1 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2013-02-13 | — | — | EP | claimed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | claimed |
| WO-2019051198-A1 | PRODRUG INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2019-03-14 | — | — | WO | disclosed |
| US-8846000-B2 | Radiolabeled PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| EP-2227233-B1 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885AGXT 365/4885CYP3A4 413/4885 |
| US-20130289083-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885AGXT 285/4885CYP3A4 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.